Literature DB >> 9099774

PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease.

E E Wang1, B J Law, J L Robinson, S Dobson, S al Jumaah, D Stephens, F D Boucher, J McDonald, I Mitchell, N E MacDonald.   

Abstract

OBJECTIVE: To determine the effects of age and respiratory syncytial virus (RSV) antibody status on frequency and severity of RSV infections in children with underlying heart or lung disease.
DESIGN: Cohort study conducted during two consecutive RSV seasons.
SETTING: Ambulatory patients at eight Canadian pediatric tertiary care centers.
METHODS: Subjects under 3 years old with underlying heart disease who were digoxin-dependent or had not received corrective cardiac surgery or with underlying lung disease were enrolled. Demographic information and an acute sera for RSV neutralizing antibody was obtained on enrollment. Weekly telephone follow-up consisting of a respiratory illness questionnaire was followed with a home visit to obtain a nasopharyngeal aspirate when there was new onset of respiratory symptoms. The specimen was used to detect RSV antigen. RSV illnesses were grouped as upper or lower respiratory tract infection (LRI) based on clinical and radiographic findings. RSV hospitalizations were considered to be those RSV infections that resulted in hospitalization.
RESULTS: Of 427 enrolled subjects, 160 had underlying lung disease only, 253 had underlying heart disease only, and 14 had both. Eleven percent and 12% of lung and heart disease groups, respectively, had an RSV LRI. Three percent and 6% of lung and heart disease groups, respectively, were hospitalized with RSV infection. A significant decrease in frequency of RSV LRI and RSV hospitalization occurred with increasing age, with a major drop in those older than 1 year vs those younger than 1 year. Acute sera were available from 422 subjects. Geometric mean RSV antibody titers demonstrated a U-shaped distribution with increasing age. The trend to lower antibody concentrations in premature infants did not reach statistical significance. The frequency of RSV infection and RSV LRI was lower in patients with antibody at a titer more than 100, although the difference for RSV hospitalization was not statistically significant. These differences remained significant after age adjustment.
CONCLUSION: Both age and RSV antibody status impact on RSV illness and LRI. Reduction in illness frequency with increasing age may lead to more informed targeting of those children most likely to benefit from RSV immune globulin prophylaxis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9099774     DOI: 10.1542/peds.99.3.e9

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  13 in total

1.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

2.  Use of palivizumab in children with congenital heart disease.

Authors: 
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

3.  The Pediatric Investigators Collaborative Network on Infections in Canada: A model for multicentre research collaboration.

Authors:  E E Wang
Journal:  Paediatr Child Health       Date:  1999-09       Impact factor: 2.253

4.  Preventing hospitalizations for respiratory syncytial virus infection.

Authors:  Joan L Robinson; Nicole Le Saux
Journal:  Paediatr Child Health       Date:  2015 Aug-Sep       Impact factor: 2.253

5.  RSV604, a novel inhibitor of respiratory syncytial virus replication.

Authors:  Joanna Chapman; Elizabeth Abbott; Dagmar G Alber; Robert C Baxter; Sian K Bithell; Elisa A Henderson; Malcolm C Carter; Phil Chambers; Ann Chubb; G Stuart Cockerill; Peter L Collins; Verity C L Dowdell; Sally J Keegan; Richard D Kelsey; Michael J Lockyer; Cindy Luongo; Pilar Najarro; Raymond J Pickles; Mark Simmonds; Debbie Taylor; Stan Tyms; Lara J Wilson; Kenneth L Powell
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

6.  Virus-Specific Antibody, Viral Load, and Disease Severity in Respiratory Syncytial Virus Infection.

Authors:  Edward E Walsh; Lu Wang; Ann R Falsey; Xing Qiu; Anthony Corbett; Jeanne Holden-Wiltse; Thomas J Mariani; David J Topham; Mary T Caserta
Journal:  J Infect Dis       Date:  2018-06-20       Impact factor: 5.226

Review 7.  Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung Disease.

Authors:  Bosco Paes; Brigitte Fauroux; Josep Figueras-Aloy; Louis Bont; Paul A Checchia; Eric A F Simões; Paolo Manzoni; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2016-11-18

Review 8.  Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease.

Authors:  Paul A Checchia; Bosco Paes; Louis Bont; Paolo Manzoni; Eric A F Simões; Brigitte Fauroux; Josep Figueras-Aloy; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2017-01-09

Review 9.  Postnatal Infections and Immunology Affecting Chronic Lung Disease of Prematurity.

Authors:  Gloria S Pryhuber
Journal:  Clin Perinatol       Date:  2015-10-01       Impact factor: 3.430

10.  Use of Medical Resources by Preterm Infants Born at Less than 33 Weeks' Gestation Following Discharge from the Neonatal Intensive Care Unit in Korea.

Authors:  Jang Hoon Lee; Yun Sil Chang
Journal:  J Korean Med Sci       Date:  2015-10-27       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.